JPWO2005023301A1 - 胆管癌治療剤および検出薬 - Google Patents

胆管癌治療剤および検出薬 Download PDF

Info

Publication number
JPWO2005023301A1
JPWO2005023301A1 JP2005513725A JP2005513725A JPWO2005023301A1 JP WO2005023301 A1 JPWO2005023301 A1 JP WO2005023301A1 JP 2005513725 A JP2005513725 A JP 2005513725A JP 2005513725 A JP2005513725 A JP 2005513725A JP WO2005023301 A1 JPWO2005023301 A1 JP WO2005023301A1
Authority
JP
Japan
Prior art keywords
antibody
glypican
cells
gpc3
bile duct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005513725A
Other languages
English (en)
Japanese (ja)
Inventor
油谷　浩幸
浩幸 油谷
正久 深山
正久 深山
直子 山内
直子 山内
鈴木　雅実
雅実 鈴木
淳彦 加藤
淳彦 加藤
土屋　政幸
政幸 土屋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Perseus Proteomics Inc
Original Assignee
Chugai Pharmaceutical Co Ltd
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Perseus Proteomics Inc filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2005023301A1 publication Critical patent/JPWO2005023301A1/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2005513725A 2003-09-04 2004-09-03 胆管癌治療剤および検出薬 Withdrawn JPWO2005023301A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003313187 2003-09-04
JP2003313187 2003-09-04
PCT/JP2004/013183 WO2005023301A1 (fr) 2003-09-04 2004-09-03 Remede et medicament de detection pour le cancer des voies biliaires

Publications (1)

Publication Number Publication Date
JPWO2005023301A1 true JPWO2005023301A1 (ja) 2006-11-02

Family

ID=34269763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005513725A Withdrawn JPWO2005023301A1 (ja) 2003-09-04 2004-09-03 胆管癌治療剤および検出薬

Country Status (4)

Country Link
US (1) US20080008710A1 (fr)
EP (1) EP1671645A4 (fr)
JP (1) JPWO2005023301A1 (fr)
WO (1) WO2005023301A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2898897A3 (fr) * 2004-07-09 2015-10-14 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-glypican 3
CN102698267B (zh) 2004-08-24 2017-07-21 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖‑3抗体的辅助疗法
BRPI0518279A2 (pt) * 2004-10-26 2008-11-11 Chugai Pharmaceutical Co Ltd anticorpo antiglipicam 3 tendo cadeia de aÇécar modificada
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
JP4787666B2 (ja) * 2006-04-28 2011-10-05 愛知県 癌の検出方法及び検出キット
CN101528258A (zh) * 2006-08-23 2009-09-09 韩国生命工学研究院 治疗肺癌的药物组合物，抑制肺癌生长或侵入的方法和治疗肺癌的方法
JP5716257B2 (ja) * 2009-02-06 2015-05-13 国立大学法人 熊本大学 胆管癌特異的糖鎖エピトープを認識するモノクローナル抗体
JP5704570B2 (ja) 2009-03-05 2015-04-22 独立行政法人産業技術総合研究所 肝内胆管がんの検出、判別方法
WO2011071393A1 (fr) * 2009-12-09 2011-06-16 Energy Saving Concepts Limited Appareil d'échange de chaleur et système de chauffage de fluide
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3141603A4 (fr) 2014-05-08 2017-12-27 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique ciblant le gpc3 pour administration à des patients pour qui la thérapie par agent thérapeutique ciblant le gpc3 est efficace
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2017002934A1 (fr) 2015-07-01 2017-01-05 中外製薬株式会社 Agent thérapeutique à gpc3 ciblé administré à un patient dans lequel un agent thérapeutiques à gpc3 ciblé est déterminé comme étant efficace

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040236080A1 (en) * 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
DE60326567D1 (de) * 2002-05-23 2009-04-23 Sunnybrook & Womens College Diagnose von hepatozellulärem karzinom

Also Published As

Publication number Publication date
WO2005023301A1 (fr) 2005-03-17
US20080008710A1 (en) 2008-01-10
EP1671645A4 (fr) 2007-07-25
EP1671645A1 (fr) 2006-06-21

Similar Documents

Publication Publication Date Title
US10696743B2 (en) Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
JP4347402B2 (ja) 抗グリピカン３抗体を含む細胞増殖抑制剤
EP2241578B1 (fr) Anticorps anti-cldn6
WO2011093097A1 (fr) Anticorps anti-dll3
JP4667372B2 (ja) 血管障害の程度の判定方法
US9644029B2 (en) Cancer diagnosis and treatment of cancer using anti-ROBO1 antibody
JP2009108047A (ja) Ｇｐｃ３の血中可溶化ｎ端ペプチドまたはｃ端ペプチドに対する抗体
JP4658926B2 (ja) 肝癌治療後の再発予測判定薬
JPWO2006064844A1 (ja) 大腸癌および／または大腸ポリープの診断ならびに術後経過観察および再発のモニター薬
JPWO2005023301A1 (ja) 胆管癌治療剤および検出薬
WO2006038588A1 (fr) Médicament permettant de contrôler l'aggravation d'une hépatite
US8940488B2 (en) Cancer diagnosis and treatment of cancer using anti-robo 1 antibody
JP4620589B2 (ja) 新規癌抗原に対する抗体
JP2013241413A (ja) 抗ｐｒｇ−３抗体を用いる癌の診断および治療

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070824

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20080326

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080326